基本信息
views: 41

Bio
Research
(i) existing NIH-funded research infrastructure in SA and (ii) the NIH large R01 mechanism to enroll 1900 pregnant women in the 1st trimester (633 WLHIV initiating DTG in pregnancy, 633 WLHIV continuing DTG use from pre-pregnancy, and 633 women without HIV) and their children, following them to two years. Within this cohort, we will first examine how HIV and/or DTG use (HIV/DTG) impacts longitudinal changes in weight and adipose tissue mass in pregnancy using air displacement plethysmography. We will further investigate pathways of excess gestational weight gain and adipose accrual by evaluating: a) the balance between caloric intake and resting energy expenditure, b) markers of systemic and adipose inflammation, gut integrity, and satiety/hunger, and c) subcutaneous adipose tissue (SAT) function and homeostasis. Following this, we will go on to examine how HIV/DTG use in pregnancy and postpartum affects maternal metabolic health postpartum (postpartum weight retention, adiposity, dysglycemia, insulin resistance, and dyslipidemia) as well as neonatal and child metabolic health (weight, adiposity, insulin resistance and dyslipidemia). To understand whether signature clusters of metabolites and lipid subspecies are associated with maternal and child metabolic health, we will apply widely targeted metabolomics techniques to measure maternal (in pregnancy) and cord blood metabolites, lipid subspecies, and eicosanoids. To address the different specific aims we will use a series of nested substudies, including smaller nested cohorts and efficient case-cohort designs, within the main cohort. This study will play a pivotal role in defining the obesogenic mechanisms and clinical consequences of DTG use in pregnancy in WLHIV and their children. The results of our study will provide insights into metabolic disease risk reduction in the context of HIV/ART, identify potential targets for interventions, and inform public health approaches to diminish chronic co-morbidities over the life course for WLHIV and their children.
(i) existing NIH-funded research infrastructure in SA and (ii) the NIH large R01 mechanism to enroll 1900 pregnant women in the 1st trimester (633 WLHIV initiating DTG in pregnancy, 633 WLHIV continuing DTG use from pre-pregnancy, and 633 women without HIV) and their children, following them to two years. Within this cohort, we will first examine how HIV and/or DTG use (HIV/DTG) impacts longitudinal changes in weight and adipose tissue mass in pregnancy using air displacement plethysmography. We will further investigate pathways of excess gestational weight gain and adipose accrual by evaluating: a) the balance between caloric intake and resting energy expenditure, b) markers of systemic and adipose inflammation, gut integrity, and satiety/hunger, and c) subcutaneous adipose tissue (SAT) function and homeostasis. Following this, we will go on to examine how HIV/DTG use in pregnancy and postpartum affects maternal metabolic health postpartum (postpartum weight retention, adiposity, dysglycemia, insulin resistance, and dyslipidemia) as well as neonatal and child metabolic health (weight, adiposity, insulin resistance and dyslipidemia). To understand whether signature clusters of metabolites and lipid subspecies are associated with maternal and child metabolic health, we will apply widely targeted metabolomics techniques to measure maternal (in pregnancy) and cord blood metabolites, lipid subspecies, and eicosanoids. To address the different specific aims we will use a series of nested substudies, including smaller nested cohorts and efficient case-cohort designs, within the main cohort. This study will play a pivotal role in defining the obesogenic mechanisms and clinical consequences of DTG use in pregnancy in WLHIV and their children. The results of our study will provide insights into metabolic disease risk reduction in the context of HIV/ART, identify potential targets for interventions, and inform public health approaches to diminish chronic co-morbidities over the life course for WLHIV and their children.
Research Interests
Papers共 565 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Yoseph Gutema,Sileshi Lulseged,Mirtie Getachew, Meklit Getahun,Zenebe Melaku, Michael Tilahun,Mesfin Shimelis, Chanie Temesgen, Tsegaye Asres, Adinew Dereje, Alemu Assefa, Esayas Tewoldebirhan,Wondimu Teferi,Alemayehu Mekonnen,Ruby Fayorsey,Allison Zerbe, Jayleen Gunn,Amy Medley,Jessica Gross,Susan Hrapcak,Elaine J. Abrams
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMESno. 1 (2025): 57-63
Tamsin K Phillips, Yolanda Gomba, Pheposadi Mogoba,Florence Phelanyane,Kim Anderson,Benjamin H Chi, Kate Clouse,Mary-Ann Davies, Jonathan Euvrard,Lucia Knight,Landon Myer,Elaine J Abrams
AIDS and behavior (2025)
The Lancet Global health (2025)
Pharmaceuticsno. 1 (2025)
PloS oneno. 12 (2024): e0315047-e0315047
CLINICAL INFECTIOUS DISEASESno. 3 (2024): 727-733
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMESno. 2 (2024): 107-116
Keolebogile N. Mmasa, Yishan Liu,Jennifer Jao,Kathleen Malee,Justine Legbedze,Shan Sun, Sam Kgole,Gosego Masasa,Mompati Mmalane,Joseph Makhema, Nelly Mafa,Elaine J. Abrams,Kathleen M. Powis,Lauren B. Bonner
AIDS Carepp.1-6, (2024)
Research square (2024)
Load More
Author Statistics
#Papers: 566
#Citation: 19906
H-Index: 73
G-Index: 112
Sociability: 8
Diversity: 4
Activity: 51
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn